Pierre M. Bet

Pierre M. Bet

Auto-generated profile, based on publicly available information

Pierre M. Bet

Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
PBPierre M. Bet
Pierre M. Bet
JHJacqueline G. Hugtenburg
Jacqueline G. Hugtenburg
BPBrenda W.J.H. Penninx
Brenda W.J.H. Penninx
WHWitte J.G. Hoogendijk
Witte J.G. Hoogendijk

15 June 2009 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
PBPierre M. Bet
Pierre M. Bet
BPBrenda W.J.H. Penninx
Brenda W.J.H. Penninx
ZBZoltan Bochdanovits
Zoltan Bochdanovits
AUAndré G. Uitterlinden
André G. Uitterlinden
ABAartjan T.F. Beekman
Aartjan T.F. Beekman
WHWitte J.G. Hoogendijk
Witte J.G. Hoogendijk

1 May 2022 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
KVKaren Vertessen
Karen Vertessen
MLMarjolein Luman
Marjolein Luman
ASAnouck Staff
Anouck Staff
PBPierre Bet
Pierre Bet
RVRalph de Vries
Ralph de Vries
JOJaap Oosterlaan
Jaap Oosterlaan
Neurocognitive deficits are at the heart of explanatory models of attention-deficit/hyperactivity disorder (ADHD), and lead to significant impairments in daily life. Determining the dosing effects of methylphenidate (MPH) on a broad range of neurocognitive functions and investigating possible impairing effects of high doses is therefore important. Placebo-controlled trials were included that investigated MPH dosing effects on neurocognitive functions in children and adolescents (aged 5-18 years) diagnosed with ADHD. Effect sizes (standardized mean differences [SMDs]) were calculated for different neurocognitive functions (baseline speed, variability in responding, nonexecutive memory and executive memory, inhibitory control, and cognitive flexibility) and, if available, for ADHD symptoms. Meta-regression analysis were used to investigate linear effects of dose (mg/kg/dose), and separate meta-analyses compared SMDs for 3 MPH dose ranges: low (0.10-0.30 mg/kg/dose), medium (0.31-0.60 mg/kg/dose), and high (0.61-1.00 mg/kg/dose). A total of 31 studies fulfilled inclusion criteria, comprising 804 children with ADHD. Methylphenidate had beneficial effects on all neurocognitive functions (d = 0.20-0.73). Significant linear dosing effects were found for ADHD symptoms and lower-order neurocognitive functions (baseline speed, variability in responding, nonexecutive memory), with greater enhancement of functioning with increasing dose. No dosing effects were found for higher-order neurocognitive functions (executive memory, inhibitory control, and cognitive flexibility). No detrimental effects of MPH were found on any of the investigated functions. Methylphenidate was superior to placebo in improving ADHD symptoms and a broad range of neurocognitive functions; however, effects sizes regarding the effects of dose vary substantially between functions. Our data highlight the importance of considering both neurocognitive and symptomatic aspects of ADHD in clinical practice.

1 December 2013 in Psychiatry Research
Verified
Journal Article
Closed access
PBPierre M. Bet
Pierre M. Bet
JHJacqueline G. Hugtenburg
Jacqueline G. Hugtenburg
BPBrenda W.J.H. Penninx
Brenda W.J.H. Penninx
ABAnton van Balkom
Anton van Balkom
WNWillem A. Nolen
Willem A. Nolen
WHWitte J.G. Hoogendijk
Witte J.G. Hoogendijk

28 August 2014 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
ESEdmée Jm Schrijver
Edmée Jm Schrijver
OVOscar J de Vries
Oscar J de Vries
AVAstrid Verburg
Astrid Verburg
KGKarola de Graaf
Karola de Graaf
PBPierre M Bet
Pierre M Bet
PNPrabath W.B. Nanayakkara
Prabath W.B. Nanayakkara
Delirium is associated with substantial morbidity and mortality rates in elderly hospitalised patients, and a growing problem due to increase in life expectancy. Implementation of standardised non-pharmacological delirium prevention strategies is challenging and adherence remains low. Pharmacological delirium prevention with haloperidol, currently the drug of choice for delirium, seems promising. However, the generalisability of randomised controlled trial results is questionable since studies have only been performed in selected postoperative hip-surgery and intensive care unit patient populations. We therefore present the design of the multicenter, randomised, double-blind, placebo-controlled clinical trial on early pharmacological intervention to prevent delirium: haloperidol prophylaxis in older emergency department patients (The HARPOON study).

31 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
RVRuud van der Veen
Ruud van der Veen
MKMarsh Königs
Marsh Königs
SBSimon Bakker
Simon Bakker
AIAndries van Iperen
Andries van Iperen
SPSaskia Peerdeman
Saskia Peerdeman
JOJaap Oosterlaan
Jaap Oosterlaan
Cognitive impairments, common sequelae of acquired brain injury (ABI), significantly affect rehabilitation and quality of life. Currently, there is no solid evidence‐base for pharmacotherapy to improve cognitive functioning after ABI, nevertheless off‐label use is widely applied in clinical practice. This meta‐analysis and meta‐regression aims to quantitatively aggregate the available evidence for the effects of pharmacological agents used in the treatment of cognitive impairments following ABI. We conducted a comprehensive search of Embase, Medline Ovid, and Cochrane Controlled Trials Register databases for randomized controlled and crossover trials. Meta‐analytic effects were calculated for each pharmaceutical agent and targeted neuromodulator system. Cognitive outcome measures were aggregated across cognitive domains. Of 8,216 articles, 41 studies (4,434 patients) were included. The noradrenergic agent methylphenidate showed a small, significant positive effect on cognitive functioning in patients with traumatic brain injury (TBI; k = 14, d = 0.34, 95% confidence interval: 0.12–0.56, P = 0.003). Specifically, methylphenidate was found to improve cognitive functions related to executive memory, baseline speed, inhibitory control, and variability in responding. The cholinergic drug donepezil demonstrated a large effect size, albeit based on a limited number of studies ( k = 3, d = 1.68, P = 0.03). No significant effects were observed for other agents. Additionally, meta‐regression analysis did not identify significant sources of heterogeneity in treatment response. Our meta‐analysis supports the use of methylphenidate for enhancing cognitive functioning in patients with TBI. Although donepezil shows potential, it warrants further research. These results could guide clinical decision making, inform practice guidelines, and direct future pharmacotherapeutic research in ABI.